LKC Technologies introduces RETeval

Gaithersburg, MD-LKC Technologies recently debuted RETeval, a handheld diabetic retinopathy (DR) screening device that enables any healthcare provider to screen for and detect sight-threatening DR. The World Health Organization estimates more than 75% of people who have diabetes for more than 20 years will have some form of DR. The Centers for Disease Control estimates that better DR detection can reduce blindness by up to 50%-60%.

RETeval is a functional test of the retina to assess the ischemic level of the retina, which, based upon published literature, correlates well to DR and other ischemic diseases such as central retinal vein occlusion, birdshot retinopathy, and others. RETeval is fast, easy to use, and provides immediate results at a very low cost without dilation.

LKC believes that any healthcare provider, from physicians’ offices to community clinics to mobile clinics in third-world countries, could easily use the RETeval and be highly effective in alerting patients to their risk of diabetic retinopathy.

The RETeval is CE marked and approved in Canada and Japan, and is being used in a number of countries such as Indonesia, Malaysia, Japan, and the U.K. LKC is developing the clinical data necessary to submit for FDA approval in the United States.